Arrowhead Pharmaceuticals, Inc. (0HI3.L)
USD 13.14
(-0.02%)
USD 13.14
(-0.02%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 115.17 Million USD | 41.18% |
| 2022 | 81.57 Million USD | 219.34% |
| 2021 | 25.54 Million USD | 20.85% |
| 2020 | 21.13 Million USD | 0.0% |
| 2019 | - USD | -100.0% |
| 2018 | 2.32 Million USD | -8.23% |
| 2017 | 2.53 Million USD | -7.12% |
| 2016 | 2.72 Million USD | 259.7% |
| 2015 | 758.34 Thousand USD | -25.82% |
| 2014 | 1.02 Million USD | -55.63% |
| 2013 | 2.3 Million USD | -1.4% |
| 2012 | 2.33 Million USD | 285.09% |
| 2011 | 606.78 Thousand USD | 21.36% |
| 2010 | 500 Thousand USD | -59.23% |
| 2009 | 1.22 Million USD | -20.2% |
| 2008 | 1.53 Million USD | 0.0% |
| 2007 | - USD | -100.0% |
| 2006 | 1.2 Million USD | 0.0% |
| 2005 | - USD | 0.0% |
| 2004 | - USD | 0.0% |
| 2003 | - USD | -100.0% |
| 2002 | 633.5 Thousand USD | 13.33% |
| 2001 | 559 Thousand USD | -0.71% |
| 2000 | 563 Thousand USD | -0.35% |
| 1999 | 565 Thousand USD | -57.72% |
| 1998 | 1.33 Million USD | 30.51% |
| 1997 | 1.02 Million USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q3 | 454.12 Million USD | 13.57% |
| 2024 Q1 | 118.57 Million USD | 2.96% |
| 2024 Q2 | 399.85 Million USD | 237.21% |
| 2023 Q3 | 82.73 Million USD | -0.06% |
| 2023 Q2 | 82.78 Million USD | 0.79% |
| 2023 FY | 115.17 Million USD | 41.18% |
| 2023 Q1 | 82.13 Million USD | 0.68% |
| 2023 Q4 | 115.17 Million USD | 39.21% |
| 2022 Q1 | 25.31 Million USD | -0.9% |
| 2022 FY | 81.57 Million USD | 219.34% |
| 2022 Q4 | 81.57 Million USD | 0.57% |
| 2022 Q3 | 81.11 Million USD | 216.75% |
| 2022 Q2 | 25.6 Million USD | 1.16% |
| 2021 Q3 | 24.14 Million USD | 1.45% |
| 2021 Q4 | 25.54 Million USD | 5.8% |
| 2021 Q2 | 23.8 Million USD | 14.05% |
| 2021 FY | 25.54 Million USD | 20.85% |
| 2021 Q1 | 20.86 Million USD | -1.28% |
| 2020 Q3 | 21.37 Million USD | 43.75% |
| 2020 FY | 21.13 Million USD | 0.0% |
| 2020 Q1 | 14.83 Million USD | 0.0% |
| 2020 Q2 | 14.86 Million USD | 0.19% |
| 2020 Q4 | 21.13 Million USD | -1.09% |
| 2019 Q3 | - USD | 0.0% |
| 2019 Q4 | - USD | 0.0% |
| 2019 Q1 | - USD | -100.0% |
| 2019 FY | - USD | -100.0% |
| 2019 Q2 | - USD | 0.0% |
| 2018 Q2 | 2.43 Million USD | -2.08% |
| 2018 FY | 2.32 Million USD | -8.23% |
| 2018 Q3 | 2.37 Million USD | -2.16% |
| 2018 Q4 | 2.32 Million USD | -2.25% |
| 2018 Q1 | 2.48 Million USD | -2.0% |
| 2017 Q4 | 2.53 Million USD | -1.93% |
| 2017 FY | 2.53 Million USD | -7.12% |
| 2017 Q3 | 2.58 Million USD | -1.86% |
| 2017 Q2 | 2.63 Million USD | -1.8% |
| 2017 Q1 | 2.68 Million USD | -1.73% |
| 2016 Q2 | 650.01 Thousand USD | -7.71% |
| 2016 FY | 2.72 Million USD | 259.7% |
| 2016 Q4 | 2.72 Million USD | -17.92% |
| 2016 Q1 | 704.28 Thousand USD | -7.13% |
| 2016 Q3 | 3.32 Million USD | 411.26% |
| 2015 Q3 | 812.16 Thousand USD | -6.19% |
| 2015 FY | 758.34 Thousand USD | -25.82% |
| 2015 Q1 | 919.16 Thousand USD | -10.09% |
| 2015 Q4 | 758.34 Thousand USD | -6.63% |
| 2015 Q2 | 865.77 Thousand USD | -5.81% |
| 2014 Q3 | 1.07 Million USD | -49.47% |
| 2014 Q4 | 1.02 Million USD | -4.92% |
| 2014 FY | 1.02 Million USD | -55.63% |
| 2014 Q1 | 2.27 Million USD | -1.14% |
| 2014 Q2 | 2.12 Million USD | -6.57% |
| 2013 FY | 2.3 Million USD | -1.4% |
| 2013 Q1 | 2.42 Million USD | 3.97% |
| 2013 Q3 | 2.31 Million USD | -0.37% |
| 2013 Q4 | 2.3 Million USD | -0.36% |
| 2013 Q2 | 2.32 Million USD | -4.47% |
| 2012 FY | 2.33 Million USD | 285.09% |
| 2012 Q3 | 2.34 Million USD | -0.29% |
| 2012 Q1 | 2.35 Million USD | 288.38% |
| 2012 Q4 | 2.33 Million USD | -0.29% |
| 2012 Q2 | 2.35 Million USD | -0.27% |
| 2011 Q2 | 519.71 Thousand USD | 3.94% |
| 2011 Q4 | 606.78 Thousand USD | 8.19% |
| 2011 FY | 606.78 Thousand USD | 21.36% |
| 2011 Q1 | 500 Thousand USD | 0.0% |
| 2011 Q3 | 560.87 Thousand USD | 7.92% |
| 2010 Q1 | 1.01 Million USD | -17.36% |
| 2010 FY | 500 Thousand USD | -59.23% |
| 2010 Q4 | 500 Thousand USD | -13.02% |
| 2010 Q3 | 574.84 Thousand USD | -27.82% |
| 2010 Q2 | 796.41 Thousand USD | -21.43% |
| 2009 Q4 | 1.22 Million USD | -14.54% |
| 2009 Q3 | 1.43 Million USD | -60.75% |
| 2009 Q1 | 3.85 Million USD | 150.94% |
| 2009 FY | 1.22 Million USD | -20.2% |
| 2009 Q2 | 3.65 Million USD | -5.2% |
| 2008 Q1 | - USD | 0.0% |
| 2008 Q2 | - USD | 0.0% |
| 2008 Q3 | - USD | 0.0% |
| 2008 Q4 | 1.53 Million USD | 0.0% |
| 2008 FY | 1.53 Million USD | 0.0% |
| 2007 Q1 | - USD | -100.0% |
| 2007 Q3 | - USD | 0.0% |
| 2007 Q4 | - USD | 0.0% |
| 2007 FY | - USD | -100.0% |
| 2007 Q2 | - USD | 0.0% |
| 2006 FY | 1.2 Million USD | 0.0% |
| 2006 Q1 | - USD | 0.0% |
| 2006 Q4 | 1.2 Million USD | 0.0% |
| 2006 Q3 | - USD | 0.0% |
| 2006 Q2 | - USD | 0.0% |
| 2005 Q1 | - USD | 0.0% |
| 2005 FY | - USD | 0.0% |
| 2005 Q4 | - USD | 0.0% |
| 2005 Q3 | - USD | 0.0% |
| 2005 Q2 | - USD | 0.0% |
| 2004 Q1 | - USD | 0.0% |
| 2004 Q3 | - USD | 0.0% |
| 2004 FY | - USD | 0.0% |
| 2004 Q4 | - USD | 0.0% |
| 2004 Q2 | - USD | 0.0% |
| 2003 Q4 | - USD | -100.0% |
| 2003 FY | - USD | -100.0% |
| 2003 Q1 | 632 Thousand USD | -0.24% |
| 2003 Q2 | 630.5 Thousand USD | -0.24% |
| 2003 Q3 | 629.5 Thousand USD | -0.16% |
| 2002 FY | 633.5 Thousand USD | 13.33% |
| 2002 Q4 | 633.5 Thousand USD | -0.24% |
| 2002 Q2 | 536.5 Thousand USD | -3.85% |
| 2002 Q1 | 558 Thousand USD | -0.18% |
| 2002 Q3 | 635 Thousand USD | 18.36% |
| 2001 FY | 559 Thousand USD | -0.71% |
| 2001 Q1 | 562.5 Thousand USD | -0.09% |
| 2001 Q2 | 562 Thousand USD | -0.09% |
| 2001 Q4 | 559 Thousand USD | -0.27% |
| 2001 Q3 | 560.5 Thousand USD | -0.27% |
| 2000 Q3 | 563.5 Thousand USD | -0.09% |
| 2000 Q4 | 563 Thousand USD | -0.09% |
| 2000 FY | 563 Thousand USD | -0.35% |
| 2000 Q2 | 564 Thousand USD | -0.09% |
| 2000 Q1 | 564.5 Thousand USD | -5.92% |
| 1999 Q2 | 1.1 Million USD | 0.0% |
| 1999 Q4 | 600 Thousand USD | 0.0% |
| 1999 Q3 | 600 Thousand USD | -45.45% |
| 1999 FY | 565 Thousand USD | -57.72% |
| 1998 Q2 | 1 Million USD | 0.0% |
| 1998 Q3 | 1.1 Million USD | 10.0% |
| 1998 Q4 | 1.1 Million USD | 0.0% |
| 1998 FY | 1.33 Million USD | 30.51% |
| 1997 FY | 1.02 Million USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Xeris Biopharma Holdings, Inc. | 229.19 Million USD | 49.749% |
| Codexis, Inc. | 22.36 Million USD | -414.984% |
| Viridian Therapeutics, Inc. | 21.04 Million USD | -447.183% |
| Organovo Holdings, Inc. | 1.39 Million USD | -8161.908% |